Patents Issued in August 9, 2018
  • Publication number: 20180222923
    Abstract: 4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Application
    Filed: August 3, 2016
    Publication date: August 9, 2018
    Inventors: Sunil Kumar KC, David Mark Wallace, Jianguo Cao, Chandramouli Chiruta, Joseph Timothy Marakovits, Venkataiah Bollu, John Hood
  • Publication number: 20180222924
    Abstract: The present disclosure provides an energy storage molecular material, crystal dielectric layer and capacitor which may solve a problem of the further increase of volumetric and mass density of reserved energy associated with some energy storage devices, and at the same time reduce cost of materials.
    Type: Application
    Filed: April 3, 2018
    Publication date: August 9, 2018
    Inventor: Pavel Lazarev
  • Publication number: 20180222925
    Abstract: The present invention provides compounds of formula (I) wherein A, B, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Amal Dakka, Luke Green, Gary Karp, Jana Narasimhan, Nikolai Naryshkin, Emmanuel Pinard, Hongyan Qi, Hasane Ratni, Nicole Risher, Marla Weetall, Matthew Woll
  • Publication number: 20180222926
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 9, 2018
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Jr, Lene Raunkjaer PETERSEN, Francesco PARLATI, Matthew I. GROSS
  • Publication number: 20180222927
    Abstract: The present invention relates to an alkoxysilane salt compound having a novel structure, a preparation method therefor, and a hair composition containing the same. The alkoxysilane salt compound increases the storage stability and the dispersion stability of a hair composition in accordance with the formation of a self-assembly in the aqueous phase and can provide a continuous conditioning effect for hair.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Jae Won YOO, Yoon Kyun HWANG, Sung-Ah BIN, Yong Jin KIM, John Hwan LEE
  • Publication number: 20180222928
    Abstract: Fluorinated cyclopentene moieties and fluorinated cyclopentene functionalized silica materials are provided. The fluorinated cyclopentene functionalized silica materials include a silica material having the fluorinated cyclopentene moiety covalently bonded thereto. Exemplary silica materials include a polysilsesquioxane, a nanosilica, a microsilica, a silica gel, a silica aerogel, or combinations thereof. The fluorinated cyclopentene moieties are based on a modification of perfluorocyclopentene (i.e., 1,2,3,3,4,4,5,5-octafluoro-1-cyclopentene) by nucleophilic substitution with an appropriate nucleophile having a reactive functional group. Methods for preparing fluorinated cyclopentene moieties and the corresponding fluorinated cyclopentene functionalized silica materials are also provided.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 9, 2018
    Applicant: Government of the United States as Represented by the Secretary of the Air Force
    Inventors: Scott Iacono, Abby Rose Jennings
  • Publication number: 20180222929
    Abstract: This invention relates to a photoinitiator compound comprising: a polyhedral oligomeric silsesquioxane (POSS) moiety and a photoinitiator moiety, wherein the photoinitiator compound having the structure according to formula (I): [R—SiO1.5]n (I), wherein n is 6, 8, 10 or 12 and R is independently selected from the group consisting of H, linear or branched (hetero)alkyl, linear or branched (hetero)alkenyl, (hetero)aryl, (hetero)alkyl aryl, (hetero)aryl alkyl and a photoinitiator moiety, wherein at least one R is a photoinitiator moiety and the photoinitiator compound is a nanoparticle. The present invention also relates to a method for the production of the photoinitiator compound of the invention, a photopolymerizable composition comprising the photoinitiator compound of the invention, the use of the photoinitiator compound of the invention for photopolymerization. The present invention is further related to a coated substrate comprising the photopolymerizable composition of the invention.
    Type: Application
    Filed: August 17, 2016
    Publication date: August 9, 2018
    Inventors: Fuke Wang, Fei Wang, Chaobin He
  • Publication number: 20180222930
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 9, 2018
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Publication number: 20180222931
    Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.
    Type: Application
    Filed: August 16, 2017
    Publication date: August 9, 2018
    Applicants: Board of Regents, The University of Texas System, Baylor College of Medicine
    Inventors: John S. McMURRAY, Pijus Kumar MANDAL, Pietro MORLACCHI, Morgan KNIGHT, David B. CORRY
  • Publication number: 20180222932
    Abstract: We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs).
    Type: Application
    Filed: August 5, 2016
    Publication date: August 9, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • Publication number: 20180222933
    Abstract: Inherently selective precursors for deposition of second or third row transition metal (e.g., tungsten or ruthenium) thin films are described. In an example, a ligand framework for second or third row transition metal complex formation includes a lithium complex.
    Type: Application
    Filed: June 18, 2015
    Publication date: August 9, 2018
    Inventor: Patricio E. ROMERO
  • Publication number: 20180222934
    Abstract: Provided is a method for decolorizing and optionally neutralizing a rhamnolipid composition comprising treating said composition with a percarbonate salt as well as the decolorized and optionally neutralized composition obtainable therefrom. Also provided is a method for improving the quality of wastewater generated during said method.
    Type: Application
    Filed: June 1, 2017
    Publication date: August 9, 2018
    Inventor: Nattaporn Lohitharn
  • Publication number: 20180222935
    Abstract: The present invention relates a process for the recovery of one or more steviol glycosides from a steviol glycoside-containing fermentation broth, which method comprises (a) providing a fermentation broth comprising one or more steviol glycosides and one or more non-steviol glycoside components; (b) separating the liquid phase of the broth from the solid phase of the broth; (c) providing an adsorbent resin; (d) contacting the liquid phase of the broth with the adsorbent resin in order to separate at least a portion of the one or more steviol glycosides from the non-steviol glycoside components, thereby to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides. The invention also relates to a purified steviol glycoside composition prepared using such a process.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventor: Igor GALAEV
  • Publication number: 20180222936
    Abstract: Described herein are methods for the synthesis of derivatives of thiosulfonate reagents. Said reagents have utility for the synthesis of phosphorothiotriesters from H-phosphonates in a stereospecific fashion.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Inventors: Gregory L. Verdine, Meena, Naoki Iwamoto, David Charles Donnell Butler
  • Publication number: 20180222937
    Abstract: The present application relates to a method of preparing compounds of Formula (A) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 9, 2018
    Inventor: Gabriel M Galvin
  • Publication number: 20180222938
    Abstract: The present invention is directed to methods for purifying a protein of interest, e.g., an antibody, from a sample comprising the protein of interest and at least one impurity, e.g., an aggregate, by employing a hydrophobic interaction chromatography (HIC) method that allows for binding of both the protein of interest and the at least one impurity under strong binding conditions. The present invention is based, at least in part, on the finding that both flow through and bind-elute techniques can be combined to achieve greater purification and recovery of a protein of interest, e.g., an antibody, under isocratic wash conditions and strong binding conditions.
    Type: Application
    Filed: January 8, 2018
    Publication date: August 9, 2018
    Applicant: AbbVie Inc.
    Inventors: Matthew Omon Herigstad, Linda E. Rich, Stephen Ming-Teh Lu, Natarajan Ramasubramanyan
  • Publication number: 20180222939
    Abstract: To provide an affinity support in which a binding property of a ligand to a target substance is improved. The affinity support contains a solid phase support and a protein ligand, wherein the protein ligand is represented by formula (1): R—R1 (1) wherein R represents a linker binding to the solid phase support, which contains a polyproline, and R1 represents a protein showing an affinity to immunoglobulin, and the R is bound to a C terminal or an N terminal of an amino acid sequence in R1.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 9, 2018
    Applicants: JSR CORPORATION, JSR LIFE SCIENCES CORPORATION
    Inventors: Takashi ICHII, Satoshi NAKAMURA, Jun-ichi YASUOKA, Kaori ITAYA, Tomonori SHIOTANI
  • Publication number: 20180222940
    Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 9, 2018
    Applicants: The Administrators of the Tulane Educational Fund, United States Department of Veterans Affairs
    Inventors: James E. ZADINA, Laszlo HACKLER
  • Publication number: 20180222941
    Abstract: The present invention provides DEPDC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 9, 2018
    Applicant: OncoTherapy Science, Inc.
    Inventors: Sachiko YAMASHITA, Tetsuro HIKICHI
  • Publication number: 20180222942
    Abstract: Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.
    Type: Application
    Filed: October 9, 2017
    Publication date: August 9, 2018
    Inventors: Jun O. Liu, Jingxin Wang, Zufeng Guo, Wei Li, Shridhar Bhat, Manisha Das
  • Publication number: 20180222943
    Abstract: A novel antimicrobial peptide is provided having an inhibitory effect on biofilms produced by biofilm-forming bacteria. The peptide is effective against wide range bacterial targets; generates no antimicrobial resistance; agglutinates bacteria cells enhancing the pathogen removal at the infectious focus; promotes biofilm eradication and prevents biofilm development. Compositions comprising the peptide are provided to treat and prevent infectious diseases, and for other uses such as the disinfection of medical and surgical materials.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 9, 2018
    Applicants: UNIVERSITAT AUTONOMA DE BARCELONA, UNIVERSITAT POMPEU FABRA
    Inventors: Ester BOIX BORRÁS, Marc TORRENT BURGAS, David ANDREU
  • Publication number: 20180222944
    Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.
    Type: Application
    Filed: December 6, 2017
    Publication date: August 9, 2018
    Inventor: Jacob E. GLANVILLE
  • Publication number: 20180222945
    Abstract: Photosynthetic microorganisms with broadened light absorption capability and increased photosynthetic activity are described. Broadened light absorption is achieved by modifying the microorganism to utilize non-native bilins. Increased photosynthetic activity results from the broadened light absorption and can also result from a decrease in self-shading. The microorganisms include Cyanobacteria, including modified Cyanobacteria.
    Type: Application
    Filed: July 7, 2016
    Publication date: August 9, 2018
    Inventors: James ROBERTS, David M. DOUGHTY
  • Publication number: 20180222946
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: January 4, 2018
    Publication date: August 9, 2018
    Inventors: Normand BLAIS, Steve LABBE, Jan POOLMAN
  • Publication number: 20180222947
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, Hemipteran, fungi and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Application
    Filed: July 8, 2016
    Publication date: August 9, 2018
    Applicants: E. I. DU PONT DE NEMOURS AND COMPANY, PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: STEPHEN M ALLEN, JENNIFER KARA BARRY, VIRGINIA CRANE, JAMES J ENGLISH, KEVIN A FENGLER, ERIC SCHEPERS, INGRID UDRANSZKY
  • Publication number: 20180222948
    Abstract: Isolated wheat proteins that are substantially free of additives, processing aids, added acids, buffers, reagents, or added enzymes and compositions formed from the isolated wheat proteins are described. Methods of forming compositions which include isolated wheat proteins that are substantially free of additives, processing aids, added acids, buffers, reagents, or added enzymes are also described.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Inventors: Normand Germain, Michel Giroux
  • Publication number: 20180222949
    Abstract: Embodiments of the invention are directed to Ubx-fusion molecules that maintain their mechanical strength and properties even after being fused with Ubx. Ubx fusions with VEGF and other growth factors, cell signaling proteins, and cell binding proteins can be used to induce angiogenesis. Ubx fibers and mesh, embedded within a tissue engineering scaffold, induce formation of vasculature within the scaffold. The presence of vasculature is necessary to provide oxygen and nutrients to other cells growing within the scaffold.
    Type: Application
    Filed: January 20, 2016
    Publication date: August 9, 2018
    Inventors: Sarah Bondos, Kayla Bayless, Kathleen Matthews, Jan Patterson, Colette Abbey, David Howell, Hao-Ching Hsiao, Kelly Churion, Shang-Pu Tsai, Sandhya Ramasamy, Dustin Porterpan, Keira Northern
  • Publication number: 20180222950
    Abstract: A method of disinfection of a surface of a subject of harmful microorganisms including pathogenic bacteria and viruses upon visible light irradiation using a genetically hybridized fluorescent silk is provided. The method includes placing a predetermined quantity of the genetically hybridized fluorescent silk i) directly on to a skin surface of a subject; or ii) on a medium and then placing the medium on the skin surface of the subject. The method further includes applying light in the visible spectrum for a predetermined amount of time to the placed quantity of genetically hybridized fluorescent silk.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 9, 2018
    Applicants: Purdue Research Foundation, REPUBLIC OF KOREA
    Inventors: Jung Woo Leem, Seung Ho Choi, Young L. Kim, Kwangho Choi, Seong-Ryul Kim, Seong-Wan Kim
  • Publication number: 20180222951
    Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
    Type: Application
    Filed: August 3, 2016
    Publication date: August 9, 2018
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Publication number: 20180222952
    Abstract: The present invention provides peptides, compositions and methods for treatment and alleviation of lysosomal storage diseases and their diagnosis and treatment, including Gaucher's Disease, and particularly which utilize one or more progranulin (PGRN) derivative or fragment, particularly fragment ND7/Pcgin.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 9, 2018
    Inventors: Chuanju LIU, Jinlong JIAN, Qingyun TIAN
  • Publication number: 20180222953
    Abstract: Certain embodiments of the invention provide a polypeptide comprising: (a) an amino acid sequence encoding a first chromophore; (b) a first linker; (c) an amino acid sequence having at least about 80% sequence identity to an amino acid sequence encoding a troponin C; (d) a second linker; and (e) an amino acid sequence encoding a second chromophore; wherein the first and second chromophores are a Förster resonance energy transfer (FRET) donor-acceptor pair; wherein the first chromophore is a donor chromophore and the second chromophore is an acceptor chromophore, or wherein the first chromophore is an acceptor chromophore and the second chromophore is a donor chromophore; and wherein the polypeptide is capable of integrating into a sarcomere. Certain embodiments of the invention also provide methods of using such polypeptides.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 9, 2018
    Inventors: Joseph M. Metzger, Anthony Vetter
  • Publication number: 20180222954
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
    Type: Application
    Filed: March 22, 2018
    Publication date: August 9, 2018
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
  • Publication number: 20180222955
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.
    Type: Application
    Filed: March 31, 2018
    Publication date: August 9, 2018
    Inventors: Jong Mook KIM, Jae Gyun JEONG
  • Publication number: 20180222956
    Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides T?RII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.
    Type: Application
    Filed: December 14, 2017
    Publication date: August 9, 2018
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Publication number: 20180222957
    Abstract: The present invention relates to modified CXCL12 polypeptides, modified CXCL12 locked monomers, and CXCL12 locked dimers. The invention further relates to methods for inhibiting signaling through CXCR4 receptors using the polypeptides of the invention.
    Type: Application
    Filed: February 2, 2018
    Publication date: August 9, 2018
    Inventors: Stephen J. McCormack, Surendra J. Chavan
  • Publication number: 20180222958
    Abstract: Polypeptides, agents, and molecules that bind lymphotoxin-beta receptor (LT?R) and/or tumor-associated antigens are disclosed. The polypeptides, agents, or molecules may include, without limitation, fusion or single-chain lymphotoxin-??? polypeptides and homodimer and heterodimer molecules comprising the lymphotoxin-??? polypeptides. Antibodies that specifically bind B7-H4 and P-CADHERIN are also disclosed. Also disclosed are methods of using the polypeptides, agents, molecules, or antibodies for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.
    Type: Application
    Filed: December 20, 2017
    Publication date: August 9, 2018
    Inventors: Austin L. GURNEY, Inkyung Park, Fumiko Takada Axelrod
  • Publication number: 20180222959
    Abstract: Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing fusion polypeptides. These fusion polypeptides contain two or more domains: (i) aptamer sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous and viral lesions, (ii) immunomodulators, such as cytokines, and optionally (iii) at least one linker joining the two domains or at the terminus of the polypeptide. In some cases, the linker is a rigid linker, e.g., a rigid helical linker. Also provided herein are methods of treating cancer and/or infectious diseases using the new fusion polypeptides.
    Type: Application
    Filed: January 25, 2018
    Publication date: August 9, 2018
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • Publication number: 20180222960
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventors: Gene M. DUBOWCHIK, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Publication number: 20180222961
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 9, 2018
    Inventors: Heiko Schuster, Janet Peper, Kevin Röhle, Philipp Wagner, Hans-Georg Rammensee
  • Publication number: 20180222962
    Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: February 2, 2018
    Publication date: August 9, 2018
    Inventors: Fritz G. Buchanan, Christian Gieffers, Oliver Hill, Susan E. Lappe, Darren C. Phillips, Meinholf Thiemann
  • Publication number: 20180222963
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: January 12, 2018
    Publication date: August 9, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180222964
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Inventors: Valeriu DAMIAN, Austin Keith DOYLE, Laura Maria HALO, Emma R. HARDING, Xuan HONG, Alan Peter LEWIS, Mark UDEN
  • Publication number: 20180222965
    Abstract: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
    Type: Application
    Filed: November 13, 2017
    Publication date: August 9, 2018
    Inventor: Gregory Alan Lazar
  • Publication number: 20180222966
    Abstract: This disclosure relates to a transgenic plant or plant tissue. In particular, this disclosure relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a sphingolipid of a fungus. Advantageously, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell (i) protects at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, (ii) inhibits the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue or plant cell, or (iii) increases the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus.
    Type: Application
    Filed: March 20, 2018
    Publication date: August 9, 2018
    Inventors: Peter Verheesen, Chris De Jonghe, Jan Geerinck, Inge Elodie Van Daele, Miguel Francesco Coleta De Bolle, João Filipe Veloso Vieira, Marnix Peferoen, Karin Thevissen, Bruno Cammue
  • Publication number: 20180222967
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20180222968
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Inventors: Robb Krumlauf, Debra Ellies
  • Publication number: 20180222969
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • Publication number: 20180222970
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Application
    Filed: March 3, 2016
    Publication date: August 9, 2018
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • Publication number: 20180222971
    Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 9, 2018
    Inventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
  • Publication number: 20180222972
    Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Ankylosing Spondylitis (AS).
    Type: Application
    Filed: November 20, 2017
    Publication date: August 9, 2018
    Applicant: Janssen Biotech, Inc.
    Inventors: Diane D. Harrison, Elizabeth C. Hsia, Lee-Lian Kim, Kim Hung Lo